Danletro

Therapeutic Segment:
Gynaecology

Generic Name:
Letrozole

Description:
Danletro tablets for oral administration contains 2.5mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water.

Indication:

  • First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
  • Adjuvant treatment of oestrogen receptor positive invasive early breast cancer in postmenopausal women.
  • Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom other antiestrogen therapy has failed.
  • Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years.
  • Neo adjuvant treatment in postmenopausal women with localized hormone receptor positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated.

Formulation:

  • Tablets

Strength:

  • 5mg / 80mg
  • 5mg / 160mg
  • 10mg / 160mg

Pack Size:

  • 1 x 14s
Danletro-packshot-mirror